Brit J Anaesth:腹部大手术后贫血与患者结局的关系

2022-07-24 MedSci原创 MedSci原创

术后贫血很常见,与术后不良预后独立相关。需要研究最佳的预防和治疗策略。

术后贫血被认为对患者的预后有不良影响,包括住院时间延长,术后并发症增加,可能伴随较差的生存率,但很少有数据支持这一观点。与术前贫血相比,术后贫血的潜在发病机制和影响在很大程度上是未知的。

近日,麻醉学领域权威杂志British Journal of Anaesthesia上发表了一篇研究文章,这项回顾性队列研究分析了来自47个中心的2983名成年患者的前瞻性数据,这些患者参加了一项评估限制性和自由静脉输液的临床试验。

该研究的主要终点是术后90天内持续残疾或死亡,次要终点包括主要脓毒症并发症、住院、患者恢复质量(采用15项恢复质量(QoR-15)评分)、再入院和术后12个月的无残疾生存率。贫血和残疾是根据世卫组织的定义确定的。研究人员采用多变量回归对基线风险和手术进行了调整。

该研究共有2983例患者符合本研究的纳入标准,其中78.5%(95%置信区间[CI]为76.7-80.1%)患者术后出现贫血。术后贫血患者术后90天内死亡或残疾的调整风险高于无贫血患者:18.2% vs 9.2%(风险比[RR]=1.51;95%CI为1.10-2.07,p=0.011);第3天和第30天QoR-15评分较低,分别为105(95%CI为87-119)和114(95%CI为99-128;P<0.001),130(95%CI为112-140) vs 139(95%CI为121-144;分别为P<0.011);调整后死亡率/感染性并发症复合风险更高,RR为2.01(95%CI为1.55-42.67;P<0.001);入住ICU(RR=2.65;95%置信区间为1.65-4.23;P<0.001);住院时间中位数较长(四分位间距[IQR]为6.6(4.4-12.4) vs 3.7(2.5-6.5)天;P<0.001)。

由此可见,术后贫血很常见,与术后不良预后独立相关。需要研究最佳的预防和治疗策略。

原始出处:

Paul S. Myles.et al.Postoperative anaemia and patient-centred outcomes after major abdominal surgery: a retrospective cohort study.British Journal of Anaesthesia.2022.https://www.bjanaesthesia.org/article/S0007-0912(22)00315-4/fulltext

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633653, encodeId=e5431633653b5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Mar 25 06:34:24 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051829, encodeId=d04d205182916, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 22 04:34:24 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722005, encodeId=ba541e2200550, content=<a href='/topic/show?id=b73f43e1224' target=_blank style='color:#2F92EE;'>#大手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43712, encryptionId=b73f43e1224, topicName=大手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecc933126179, createdName=Smile2691, createdTime=Sat Jun 17 14:34:24 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480064, encodeId=a0bf14800643a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Tue Jul 26 01:34:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
    2023-03-25 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633653, encodeId=e5431633653b5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Mar 25 06:34:24 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051829, encodeId=d04d205182916, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 22 04:34:24 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722005, encodeId=ba541e2200550, content=<a href='/topic/show?id=b73f43e1224' target=_blank style='color:#2F92EE;'>#大手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43712, encryptionId=b73f43e1224, topicName=大手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecc933126179, createdName=Smile2691, createdTime=Sat Jun 17 14:34:24 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480064, encodeId=a0bf14800643a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Tue Jul 26 01:34:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633653, encodeId=e5431633653b5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Mar 25 06:34:24 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051829, encodeId=d04d205182916, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 22 04:34:24 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722005, encodeId=ba541e2200550, content=<a href='/topic/show?id=b73f43e1224' target=_blank style='color:#2F92EE;'>#大手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43712, encryptionId=b73f43e1224, topicName=大手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecc933126179, createdName=Smile2691, createdTime=Sat Jun 17 14:34:24 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480064, encodeId=a0bf14800643a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Tue Jul 26 01:34:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633653, encodeId=e5431633653b5, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Mar 25 06:34:24 CST 2023, time=2023-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051829, encodeId=d04d205182916, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Nov 22 04:34:24 CST 2022, time=2022-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722005, encodeId=ba541e2200550, content=<a href='/topic/show?id=b73f43e1224' target=_blank style='color:#2F92EE;'>#大手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43712, encryptionId=b73f43e1224, topicName=大手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecc933126179, createdName=Smile2691, createdTime=Sat Jun 17 14:34:24 CST 2023, time=2023-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480064, encodeId=a0bf14800643a, content=<a href='/topic/show?id=f9e0530e169' target=_blank style='color:#2F92EE;'>#患者结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53071, encryptionId=f9e0530e169, topicName=患者结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=faa67597457, createdName=ms5906905816781247, createdTime=Tue Jul 26 01:34:24 CST 2022, time=2022-07-26, status=1, ipAttribution=)]

相关资讯

JAMA Intern Med:口服Daprodustat方案治疗慢性肾病贫血

Daprodustat对慢性肾病贫血患者的治疗效果与阿法达贝泊相当,是一种有效地口服促红细胞生成治疗方案。

血红蛋白156g/L,竟然还缺铁?

血常规岗位,一张验单引起了我的注意,该患者红细胞增高、血红蛋白增高,但是MCV、MCH、MCHC都是减低

少见,重度贫血伴钩虫感染,竟是大细胞性贫血?

虫卵短椭圆形,壳薄,无色透明,卵内含较多灰色颗粒细胞,初步确认为钩虫卵。病例为一名69岁的女性患者,以面色苍白、头晕、乏力1周入院。

骨髓涂片中出现Auer小体样包涵体浆细胞增多会是MM吗?

MM的特征为单克隆浆细胞在骨髓中增殖,导致高钙血症、肾功能损害、贫血和骨质破坏等终末器官损害。

CSCO肿瘤相关性贫血临床实践指南发布更新

EPO 36000U每周1次方案成为MDS治疗I级推荐!

贫血何所因,“自身”找原因

神清,气平,皮肤巩膜轻度黄染,口唇稍苍白,浅表淋巴结无肿大,双肺呼吸音清,未闻及干湿罗音,心率84次/分,律齐,各瓣膜听诊区未闻及病理性杂音,腹软,未见手术疤痕,未及包块、肠型,无肌卫、肌紧张,无压痛